# AgomAb Therapeutics NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agomab-therapeutics

- Industry: Biotechnology
- Headquarters: Antwerpen, Belgium
- Website: www.agomab.com
- Total disclosed funding: $322M
- Latest round: Series D (Nov 14, 2024)
- Investors on record: 18

## About

Based in Belgium, AgomAb Therapeutics NV is a biopharmaceutical company focused on developing innovative therapies for restoring organ function and treating fibrotic diseases. AgomAb Therapeutics NV, founded in 2017 in Ghent, Belgium, specializes in creating therapies for fibrotic diseases. In February 2026, AgomAb Therapeutics NV raised USD 200 million in an IPO, selling 12.5 million shares at?USD 16 per share per share at Nasdaq, under the ticker "AGMB". As of March 2026, Tim Knotnerus serves as Chief Executive Officer. AgomAb Therapeutics NV develops innovative therapies specifically targeting fibrotic diseases. Its lead product, AGMB-129, is an oral small molecule inhibitor aimed at treating Fibrostenosing Crohn’s Disease (FSCD), currently undergoing clinical testing in the STENOVA1 Phase 2a trial across the USA, Canada, and Europe. While specific revenue figures are not disclosed, AgomAb's revenue structure is likely based on partnerships and clinical trial outcomes in the biopharmaceutical sector, involving agreements for clinical trial participation, milestone payments, and potential royalties upon successful commercialization. The company will use the February 2026 funding for research and development purposes.

## Funding rounds

- Series D, Nov 14, 2024, $87M — Canaan Partners, Andera Partners, EQT Life Sciences, Omnes Capital, Pontifax Venture Capital, Boehringer Ingelheim Venture, Redmile Group, Sanofi, Invus Financial Advisors, Cormorant Asset Management, Walleye Capital, V-Bio Ventures, AdBio Partners, Asabys Partners, Fidelity Management and Research Company, Pfizer Breakthrough Growth Initiative, Dawn Biopharma
- Series C, Oct 16, 2023, $100M — KKR, Canaan Partners, EQT Life Sciences, Asabys Partners, Fidelity Management and Research Company, Dawn Biopharma
- Series B, Jul 13, 2022, $39M — Redmile Group, Walleye Capital, Asabys Partners, Pfizer Breakthrough Growth Initiative
- Series B, Nov 5, 2021, $70M — Andera Partners, Omnes Capital, Pontifax Venture Capital, Boehringer Ingelheim Venture, Redmile Group, Cormorant Asset Management, V-Bio Ventures, AdBio Partners
- Series A, Nov 12, 2020, $26M — Omnes Capital, Pontifax Venture Capital, Boehringer Ingelheim Venture, V-Bio Ventures, AdBio Partners
- Series A, Oct 10, 2019 — Andera Partners

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B, Series D
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series B, Series D
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B, Series D
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B, Series D
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A, Series B, Series D
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Series A, Series B, Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series D
- Walleye Capital — Series B, Series D
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series B, Series C, Series D
- Pfizer Breakthrough Growth Initiative — Series B, Series D
- KKR (https://capitalatlas.ai/funds/kkr) — Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C, Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series C, Series D
- Fidelity Management and Research Company — Series C, Series D
- Dawn Biopharma — Series C, Series D
- Sanofi — Series D
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series D